[ad_1] Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market…
[ad_1] An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right…
[ad_1] Monty Rakusen | Digitalvision | Getty Images If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don’t need to look much further than weight loss drugs. On the human side, Novo Nordisk and Eli Lilly struggled to meet the demand for Ozempic, Wegovy, Mounjaro…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. U.S. stocks were trending lower as investors awaited important inflation data and mulled over more quarterly earnings. January’s PCE price index – the Federal Reserve’s preferred measure of…
[ad_1] Image of a healthy liver not ravaged by fatty liver disease. BSIP | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drugmakers aren’t just racing to develop drugs that treat obesity. They’re also competing to expand the uses of those weight loss treatments,…
[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank of America analyst Geoff Meacham has been very bullish about the opportunity, which he calls “unprecedented” given the prevalence of obesity and the huge…
[ad_1] Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 90% on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow…
[ad_1] The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of color. Health officials now face a challenge in finding a way to provide equitable access to the costly treatments. The crippling episodes of pain…
[ad_1] Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used…
